Market Overview:
The global schizophrenia therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of schizophrenia, rising awareness about available treatments, and the launch of novel therapies. Based on type, the global schizophrenia therapeutics market is segmented into first-generation antipsychotic drugs, second-generation antipsychotic drugs, and third-generation antipsychotic drugs. The first-generation antipsychotic drugs segment is expected to account for the largest share of the global schizophrenia therapeutics market in 2018. This segment is also projected to grow at a CAGR of 5.4% during the forecast period from 2018 to 2030. Factors such as high incidence rates and large patient population are contributing to the growth of this segment.
Product Definition:
Schizophrenia Therapeutics is a term used to describe the use of drugs and other treatments to manage schizophrenia. Schizophrenia is a mental illness that affects how people think, feel, and behave. It can cause hallucinations (hearing or seeing things that are not there), delusions (believing things that are not true), and disorganized thinking.
First-Generation Antipsychotic Drugs:
First-generation antipsychotics (FGAs) are the most commonly prescribed type of antipsychotic drug. They work by decreasing the activity of serotonin, dopamine, and norepinephrine receptors in the brain. FGAs have a lower risk of causing weight gain, diabetes, and cardiovascular problems than second-generation or third-generation antipsychotics.
Second-Generation Antipsychotic Drugs:
Second-generation antipsychotic drugs are used for the treatment of schizophrenia. The global market is expected to grow at a CAGR of XX% over the forecast period. Increasing prevalence of schizophrenia and growing awareness about its symptoms such as hallucinations, inability to execute day-to-day functions are some key factors driving this market’s growth.
Application Insights:
The other application segment includes the use of antipsychotics in the treatment of non-schizophrenia psychotic disorders, such as bipolar disorder and major depression. The growing prevalence of these disorders is anticipated to fuel market growth during the forecast period.
In terms of revenue, hospital applications dominated with a share estimated at over 60% in 2017 owing to high usage rates for treating acute psychosis in patients suffering from a mental health crisis or emergency situation. This is supported by increasing government initiatives that aim to provide better care facilities for schizophrenic patients across hospitals and clinics within each country.
Regional Analysis:
North America dominated the global schizophrenia therapeutics market in 2017. This can be attributed to favorable government initiatives, increasing prevalence of the disease, rising awareness about early diagnosis and treatment, high healthcare expenditure levels, and better coverage for mental health issues compared with physical health conditions. Moreover, new drug approvals in this region are estimated to rise at a steady pace over the forecast period. For instance; in 2015-2016; North America accounted for 27% of all new drug approvals globally.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to improving economic status.
Growth Factors:
- Increasing incidence of schizophrenia
- Growing awareness about available treatments for schizophrenia
- Rising demand for better and more effective therapies for schizophrenia
- Availability of government funding for research on schizophrenia therapies
- Growing number of clinical studies on new potential therapies for schizophrenia
Scope Of The Report
Report Attributes
Report Details
Report Title
Schizophrenia Therapeutics Market Research Report
By Type
First-Generation Antipsychotic Drugs, Second-Generation Antipsychotic Drugs, Third-Generation Antipsychotic Drugs
By Application
Hospitals, Clinics, Other
By Companies
AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Alkermes, AbbVie, Amgen, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Schizophrenia Therapeutics Market Report Segments:
The global Schizophrenia Therapeutics market is segmented on the basis of:
Types
First-Generation Antipsychotic Drugs, Second-Generation Antipsychotic Drugs, Third-Generation Antipsychotic Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Alkermes
- AbbVie
- Amgen
- Bristol-Myers Squibb
Highlights of The Schizophrenia Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- First-Generation Antipsychotic Drugs
- Second-Generation Antipsychotic Drugs
- Third-Generation Antipsychotic Drugs
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Schizophrenia Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Schizophrenia therapeutics is the application of pharmacological and/or psychological interventions to treat schizophrenia.
Some of the major players in the schizophrenia therapeutics market are AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Alkermes, AbbVie, Amgen, Bristol-Myers Squibb.
The schizophrenia therapeutics market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Schizophrenia Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Schizophrenia Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Schizophrenia Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Schizophrenia Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Schizophrenia Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Schizophrenia Therapeutics Market Size and Y-o-Y Growth
4.5.2 Schizophrenia Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 First-Generation Antipsychotic Drugs
5.2.2 Second-Generation Antipsychotic Drugs
5.2.3 Third-Generation Antipsychotic Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Schizophrenia Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Schizophrenia Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 First-Generation Antipsychotic Drugs
9.6.2 Second-Generation Antipsychotic Drugs
9.6.3 Third-Generation Antipsychotic Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 First-Generation Antipsychotic Drugs
10.6.2 Second-Generation Antipsychotic Drugs
10.6.3 Third-Generation Antipsychotic Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 First-Generation Antipsychotic Drugs
11.6.2 Second-Generation Antipsychotic Drugs
11.6.3 Third-Generation Antipsychotic Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 First-Generation Antipsychotic Drugs
12.6.2 Second-Generation Antipsychotic Drugs
12.6.3 Third-Generation Antipsychotic Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 First-Generation Antipsychotic Drugs
13.6.2 Second-Generation Antipsychotic Drugs
13.6.3 Third-Generation Antipsychotic Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Schizophrenia Therapeutics Market: Competitive Dashboard
14.2 Global Schizophrenia Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Eli Lilly
14.3.3 GlaxoSmithKline
14.3.4 Johnson & Johnson
14.3.5 Alkermes
14.3.6 AbbVie
14.3.7 Amgen
14.3.8 Bristol-Myers Squibb
